CVC Acquires Therakos Business from Mallinckrodt for $925M
August 5, 2024
CVC Capital Partners Fund IX agreed to acquire the Therakos extracorporeal photopheresis business from Mallinckrodt plc for $925 million in a carve-out transaction. CVC said it will invest in further research, indication expansion and geographic growth of Therakos while key Therakos employees will transition with the business; Mallinckrodt will use proceeds to substantially reduce net debt.
- Buyers
- CVC Capital Partners Fund IX
- Targets
- Therakos
- Sellers
- Mallinckrodt plc
- Industry
- Medical Devices
- Location
- New Jersey, United States
- Transaction Type
- Divestiture
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.